Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Bio Path stock (BPTH)

Buy Bio Path stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Bio Path is a biotechnology business based in the US. Bio Path shares (BPTH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio Path employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Bio Path stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Bio Path stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BPTH. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Bio Path stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Not rated yet
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bio Path stock price (NASDAQ: BPTH)

Use our graph to track the performance of BPTH stocks over time.

Bio Path shares at a glance

Information last updated 2024-07-14.
Latest market close$1.83
52-week range$1.59 - $30.00
50-day moving average $2.26
200-day moving average $6.70
Wall St. target price$20.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-25.26

Is it a good time to buy Bio Path stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bio Path price performance over time

Historical closes compared with the close of $1.83 from 2024-07-18

1 week (2024-07-12) -6.63%
1 month (2024-06-18) -19.38%
3 months (2024-04-19) -57.34%
6 months (2024-01-19) 349.63%
1 year (2023-07-19) 39.69%
2 years (2022-07-19) -51.59%
3 years (2021-07-19) 6.22
5 years (2019-07-19) 13.72

Bio Path financials

Gross profit TTM $0
Return on assets TTM -138.36%
Return on equity TTM -430.79%
Profit margin 0%
Book value $-3.48
Market Capitalization $4.1 million

TTM: trailing 12 months

Bio Path share dividends

We're not expecting Bio Path to pay a dividend over the next 12 months.

Have Bio Path's shares ever split?

Bio Path's shares were split on a 1:20 basis on 22 February 2024. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bio Path shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bio Path shares which in turn could have impacted Bio Path's share price.

Bio Path share price volatility

Over the last 12 months, Bio Path's shares have ranged in value from as little as $1.591 up to $29.998. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio Path's is 0.283. This would suggest that Bio Path's shares are less volatile than average (for this exchange).

Bio Path overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas. .

Frequently asked questions

What percentage of Bio Path is owned by insiders or institutions?
Currently 0.103% of Bio Path shares are held by insiders and 1.151% by institutions.
How many people work for Bio Path?
Latest data suggests 10 work at Bio Path.
When does the fiscal year end for Bio Path?
Bio Path's fiscal year ends in December.
Where is Bio Path based?
Bio Path's address is: 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401
What is Bio Path's ISIN number?
Bio Path's international securities identification number is: US09057N3008
What is Bio Path's CUSIP number?
Bio Path's Committee on Uniform Securities Identification Procedures number is: 09057N300

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site